GS
DYN icon

GTS Securities’s Dyne Therapeutics DYN Stock Holding History

GTS Securities’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-58,200
Closed -$1.65M – 4021
2024
Q1 		$1.65M Buy
58,200
+28,400
+95% +$642K ﹤0.01% 1601
2023
Q4 		$396K Buy
+29,800
New +$291K ﹤0.01% 2980

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GTS Securities's DYN Position: Q2 2024 in Review

GTS Securities sold out of Dyne Therapeutics (DYN) in Q2 2024, closing a stake of 18,613 shares — an estimated $528K sold.

GTS Securities first reported a position in DYN in Q1 2024 and held it in 1 quarter. The position peaked at $528K in Q1 2024. 193 funds tracked by Wall St. Rank hold DYN as of Q2 2024.

  • GTS Securities reported no remaining Dyne Therapeutics position as of Q2 2024 after selling out during the quarter.
  • GTS Securities sold 18,613 Dyne Therapeutics shares in Q2 2024, an estimated $528K.
  • GTS Securities first reported a position in Dyne Therapeutics in Q1 2024 and held it in 1 quarter.
  • GTS Securities's Dyne Therapeutics position peaked at $528K in Q1 2024.
  • 193 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2024.

Based on GTS Securities's 13F filing for Q2 2024, filed 14 Aug 2024.